Bunnage Mark E. 4

What Happened
Mark E. Bunnage, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals (VRTX), disposed of a total of 1,202 shares in two transactions. On 2026-02-24, 582 shares were disposed at $485.11 each (≈ $282,334) to cover a tax liability or exercise cost (transaction code F). On 2026-02-25, he sold 620 shares in the open market at $486.35 each (≈ $301,537). Both transactions are sales (not purchases), totaling roughly $583,871. The initial 2/24 disposition was made pursuant to a company-approved Rule 10b5-1 trading plan entered on 2025-11-26.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 582 shares @ $485.11 (F — tax withholding/payment) ≈ $282,334
  • 2026-02-25: 620 shares @ $486.35 (S — open market sale) ≈ $301,537
• Total disposed: 1,202 shares for ≈ $583,871.
• Shares owned after transaction: Not provided in the excerpt of the filing.
• Footnote: The 2/24 (F) transaction was made pursuant to Dr. Bunnage’s company‑approved Rule 10b5-1 trading plan entered 11/26/2025.
• Filing timeliness: Form 4 filed 2026-02-26 for transactions on 2/24–2/25 — appears timely (not flagged late).

Context

• Code F typically indicates shares were surrendered/withheld to satisfy taxes or exercise costs (common when equity vests or options are exercised). The separate S-coded trade was an open-market sale.
• Sales by executives can be routine (tax withholding, trading plans) and do not necessarily indicate a change in company outlook; purchases are generally more informative about insider bullishness.